Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat

por Hohmann, Nicolas, Bozorgmehr, Farastuk, Christopoulos, Petros, Mikus, Gerd, Blank, Antje, Burhenne, Jürgen, Thomas, Michael, Haefeli, Walter E.
Publicado 2020

Awareness of predatory journals and open access among medical oncologists: results of an online survey

por Richtig, Georg, Richtig, Erika, Böhm, Alexandra, Oing, Christoph, Bozorgmehr, Farastuk, Kruger, Stephan, Kiesewetter, Barbara, Zielinski, Christoph, Berghoff, Anna S
Publicado 2019

Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to f...

por Bozorgmehr, Farastuk, Chung, Inn, Christopoulos, Petros, Krisam, Johannes, Schneider, Marc A., Brückner, Lena, Mueller, Daniel Wilhelm, Thomas, Michael, Rieken, Stefan
Publicado 2023

Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durval...

por Bozorgmehr, Farastuk, Chung, Inn, Christopoulos, Petros, Krisam, Johannes, Schneider, Marc A., Brückner, Lena, Mueller, Daniel Wilhelm, Thomas, Michael, Rieken, Stefan
Publicado 2020

Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial

por Kuon, Jonas, Hommertgen, Adriane, Krisam, Johannes, Lasitschka, Felix, Stenzinger, Albrecht, Blasi, Miriam, Bozorgmehr, Farastuk, Maenz, Martin, Kieser, Meinhard, Schneider, Marc, Thomas, Michael
Publicado 2020

Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer

por Elsayed, Mei, Bozorgmehr, Farastuk, Kazdal, Daniel, Volckmar, Anna-Lena, Sültmann, Holger, Fischer, Jürgen R., Kriegsmann, Mark, Stenzinger, Albrecht, Thomas, Michael, Christopoulos, Petros
Publicado 2021

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protoco...

por Christopoulos, Petros, Bozorgmehr, Farastuk, Brückner, Lena, Chung, Inn, Krisam, Johannes, Schneider, Marc A., Stenzinger, Albrecht, Eickhoff, Regina, Mueller, Daniel W., Thomas, Michael
Publicado 2021

Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients

por von Eiff, Damian, Bozorgmehr, Farastuk, Chung, Inn, Bernhardt, Denise, Rieken, Stefan, Liersch, Stephan, Muley, Thomas, Kobinger, Sonja, Thomas, Michael, Christopoulos, Petros, Steins, Martin
Publicado 2020

Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report

por Volckmar, Anna-Lena, Endris, Volker, Bozorgmehr, Farastuk, Lier, Clemens, Porcel, Carlota, Kirchner, Martina, Leichsenring, Jonas, Penzel, Roland, Thomas, Michael, Schirmacher, Peter, Warth, Arne, Stenzinger, Albrecht
Publicado 2016

Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial

por Bozorgmehr, Farastuk, Hommertgen, Adriane, Krisam, Johannes, Lasitschka, Felix, Kuon, Jonas, Maenz, Martin, Huber, Peter E., König, Laila, Kieser, Meinhard, Debus, Juergen, Thomas, Michael, Rieken, Stefan
Publicado 2019

Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease – a randomized, open-label, multicenter phase II trial

por Bozorgmehr, Farastuk, Christopoulos, Petros, Chung, Inn, Cvetkovic, Jelena, Feißt, Manuel, Krisam, Johannes, Schneider, Marc A., Heußel, Claus Peter, Kreuter, Michael, Müller, Daniel W., Thomas, Michael, Rieken, Stefan
Publicado 2022

Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma

por Fisch, David, Bozorgmehr, Farastuk, Kazdal, Daniel, Kuon, Jonas, Klotz, Laura V., Shah, Rajiv, Eichhorn, Florian, Kriegsmann, Mark, Schneider, Marc A., Muley, Thomas, Stenzinger, Albrecht, Bischoff, Helge, Christopoulos, Petros
Publicado 2021

Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy

por Bernhardt, Denise, Aufderstrasse, Sophie, König, Laila, Adeberg, Sebastian, Bozorgmehr, Farastuk, Christopoulos, Petros, Shafie, Rami A El, Hörner-Rieber, Juliane, Kappes, Jutta, Thomas, Michael, Herth, Felix, Steins, Martin, Debus, Jürgen, Rieken, Stefan
Publicado 2018

Comorbidity in limited disease small-cell lung cancer: Age-adjusted Charlson comorbidity index and its association with overall survival following chemoradiotherapy

por Fink, Christoph A., Weykamp, Fabian, Adeberg, Sebastian, Bozorgmehr, Farastuk, Christopoulos, Petros, Lang, Kristin, König, Laila, Hörner-Rieber, Juliane, Thomas, Michael, Steins, Martin, El-Shafie, Rami A., Rieken, Stefan, Bernhardt, Denise, Debus, Jürgen
Publicado 2023

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer

por Bozorgmehr, Farastuk, Kazdal, Daniel, Chung, Inn, Kirchner, Martina, Magios, Nikolaus, Kriegsmann, Mark, Allgäuer, Michael, Klotz, Laura V., Muley, Thomas, El Shafie, Rami A., Fischer, Jürgen R., Faehling, Martin, Stenzinger, Albrecht, Thomas, Michael, Christopoulos, Petros
Publicado 2021

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors

por Rheinheimer, Stephan, Heussel, Claus-Peter, Mayer, Philipp, Gaissmaier, Lena, Bozorgmehr, Farastuk, Winter, Hauke, Herth, Felix J., Muley, Thomas, Liersch, Stephan, Bischoff, Helge, Kriegsmann, Mark, El Shafie, Rami A., Stenzinger, Albrecht, Thomas, Michael, Kauczor, Hans-Ulrich, Christopoulos, Petros
Publicado 2020

Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages

por Janke, Florian, Bozorgmehr, Farastuk, Wrenger, Sabine, Dietz, Steffen, Heussel, Claus P., Heussel, Gudula, Silva, Carlos F., Rheinheimer, Stephan, Feisst, Manuel, Thomas, Michael, Golpon, Heiko, Günther, Andreas, Sültmann, Holger, Muley, Thomas, Janciauskiene, Sabina, Meister, Michael, Schneider, Marc A.
Publicado 2020

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer

por Daniello, Lea, Elshiaty, Mariam, Bozorgmehr, Farastuk, Kuon, Jonas, Kazdal, Daniel, Schindler, Hannah, Shah, Rajiv, Volckmar, Anna-Lena, Lusky, Fabienne, Diekmann, Leonore, Liersch, Stephan, Faehling, Martin, Muley, Thomas, Kriegsmann, Mark, Benesova, Karolina, Stenzinger, Albrecht, Thomas, Michael, Christopoulos, Petros
Publicado 2021

Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Admin...

por Eichkorn, Tanja, Bozorgmehr, Farastuk, Regnery, Sebastian, Dinges, Lisa A., Kudak, Andreas, Bougatf, Nina, Weber, Dorothea, Christopoulos, Petros, Muley, Thomas, Kobinger, Sonja, König, Laila, Hörner-Rieber, Juliane, Adeberg, Sebastian, Heussel, Claus Peter, Thomas, Michael, Debus, Jürgen, El Shafie, Rami A.
Publicado 2020

C. elegans as Model for the Study of High Glucose– Mediated Life Span Reduction

por Schlotterer, Andreas, Kukudov, Georgi, Bozorgmehr, Farastuk, Hutter, Harald, Du, Xueliang, Oikonomou, Dimitrios, Ibrahim, Youssef, Pfisterer, Friederike, Rabbani, Naila, Thornalley, Paul, Sayed, Ahmed, Fleming, Thomas, Humpert, Per, Schwenger, Vedat, Zeier, Martin, Hamann, Andreas, Stern, David, Brownlee, Michael, Bierhaus, Angelika, Nawroth, Peter, Morcos, Michael
Publicado 2009